JPRN-UMIN000028439招募中未知
Precision Cancer Medicine Registration Study of Omics Data from Genomic Information Analysis Leading to New Effective Therapy - PROFILE study
Tokyo Medical and Dental University Cancer Center0 个研究点目标入组 500 人开始时间: 2017年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1years-old 至 120years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •- those who cannot consent
研究者
相似试验
已完成
不适用
Developing a Cancer database for Shirdi Sai Baba Cancer and Research Centre.CTRI/2018/10/016139Dr Kanav Khera Proff130
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerEUCTR2017-003134-85-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.318
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerTreatment of advanced NSCLCMedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003134-85-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.192
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerTreatment of advanced NSCLCMedDRA version: 21.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003134-85-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.318
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerStage IV non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864CTIS2022-500990-16-00Merck Sharp & Dohme LLC266